Ablynx Ups Profile Stateside With $200m Nasdaq Listing
Executive Summary
Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.
You may also be interested in...
Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom
A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.
Products For Flu, Lung Cancer, HIV And TTP Enter Final Stages Of Assessment In EU
Products in the final stages of pre-marketing evaluation at the European Medicines Agency include drugs for influenza, NSCLC, aTTP and HIV infection.
Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.